Boundless Bio, Inc. (BOLD): R&D Expense
$44.84M
Year ended 2025-12-31
$44.20M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.84M | -18.9% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $55.27M | +29.6% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $42.64M | n/a | 2025-03-27, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $44.84M | -18.9% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $52.65M | +56.7% |
| Veradermics, Inc (MANE) | 2025-12-31 | $62.06M | +166.6% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $13.42M | +38.3% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $68.73M | -17.6% |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $25.67M | -55.1% |
Compare BOLD, PGEN, XLO, AQST side by side · Screen every company in Pharmaceutical Preparations ↗